BIOTECHNOLOGY

“It’s rewarding to know that our product can help expedite the search for a COVID-19 vaccine,” said TriAltus Bioscience CEO Bob Shufflebarger. “Our CL7/Im7 system is helping Dr. Hu and his colleagues attain high protein purity in a single-step process that saves critical time and boosts research productivity.”

The FDA has approved a Phase II clinical trial evaluating efficacy and safety of the Hope Bioscience autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19.

NxGen MDx notes, the rise in U.S. cases of COVID-19, a highly contagious and sometimes fatal respiratory illness, has concerned health officials and spurred calls from lawmakers for action to expand testing capacity to slow its spread.

IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX Therapeutics.

With the updated guidance from FDA issued on March 16, BGI's detection kit is eligible to be used immediately to expedite clinical testing for the novel coronavirus.

The phase 2 clinical trial of RLF-100 (Aviptadil) is being coordinated with the Senior Leadership of the Government of Israel for the treatment of Acute Respiratory Distress Syndrome in patients with COVID-19 infection. The trial is being coordinated by Prof. Jonathan Javitt, MD, MPH, acting Chairman of the Scientific Advisory Board of Relief in coordination with Dr. Miki Halberthal, MD, CEO of the Rambam Healthcare Campus and Dr. Boaz Lev, head of Israel’s COVID task force and former Director-General of Israel’s Ministry of Health.

As the only FDA-inspected lab of its type in the region, Agilex Biolabs is located in Adelaide, South Australia, in a science and biotech specialist hub. The company specializes in bioanalysis for small molecules and biologics for PK, immunogenicity, and biomarkers utilizing the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).

CEL-SCI notes the LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell-mediated T cell responses and reduce viral load.

"We have been working on multiple solutions to augment our NxTAG and ARIES offerings in order to facilitate and automate the detection of SARS-CoV-2," said Nachum "Homi" Shamir, President and CEO of Luminex.